Can-Fite BioPharma
About Science Pipeline Investor Information Contact Us

Investor Information

Investor Information

Profile

Business Description

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of inflammatory, cancer, and metabolic diseases. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoints in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in approximately 2,000 patients in clinical studies to date.

Address:
10 Bareket Street, Kiryat Matalon
P.O. Box 7537
Petah-Tikva, 49170

Website:
http://www.canfite.com/

Email:
info@canfite.co.il

Telephone:
+972-3-9241114
(800) 716-4880

Fax:
+972-3-9249378

Details

CEO:
Pnina Fishman, Ph.D.

Issue Type:
On the NYSE U.S. ADRs are traded at a ratio of 1 ADR = 30 common shares

Auditors:
Ernst & Young Israel

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

Sub-Industry:
Biotechnology

NAICS:
541711

SIC:
2834